CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

somatrogon

Last Updated: April 5, 2021
Result type: Reports
Project Number: SR0683-000
Product Line: Reimbursement Review

Generic Name: somatrogon

Brand Name: TBC

Manufacturer: Pfizer Canada ULC

Therapeutic Area: Growth hormone deficiency

Indications: ​Long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone.

Manufacturer Requested Reimbursement Criteria1: ​Long-term treatment of pediatric patients who have growth hormone deficiency.

Submission Type: Initial

Project Status: Pending

Call for patient/clinician input open: April 5, 2021

Call for patient/clinician input closed: May 28, 2021

Anticipated Date: June 3, 2021

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback